Fliss D M, Krauss M, Gorodischer R, Bearman J, Lieberman A
Harefuah. 1989 Dec 1;117(11):361-3.
The efficacy of cefaclor and of trimethoprim-sulfamethoxazole (TMP-SMX) in the management of recurrent otitis media was evaluated in a randomized single-blind controlled trial. The median age of the patients was 12 months (range 5-37); there were 37 boys and 19 girls. All had received 1 or more courses of antibacterials for acute otitis media in the previous 2-3 weeks. 27 were treated with oral cefaclor suspension, 40 mg/kg/day in 3 divided doses, and 29 with 1 mg/kg/day of TMP-SMX (trimethoprim 8 mg, sulfamethoxazole 40 mg) in 2 divided doses, each group for 10 days. 70% of the cefaclor group and 90% of the TMP-SMX group were cured after the 10 days of therapy (0.1 greater than p greater than 0.05). Results were not better on the 21st day as compared with the 10th. Our data indicate a mild preference for TMP-SMX (although p was not less than 0.05), since it needs to be given only twice a day and costs less than cefaclor.
在一项随机单盲对照试验中，评估了头孢克洛和甲氧苄啶-磺胺甲恶唑（TMP-SMX）治疗复发性中耳炎的疗效。患者的中位年龄为12个月（范围5 - 37个月）；有37名男孩和19名女孩。所有患者在过去2 - 3周内均接受过1个或更多疗程的急性中耳炎抗菌治疗。27例患者接受口服头孢克洛混悬液治疗，40mg/kg/天，分3次给药；29例患者接受1mg/kg/天的TMP-SMX（甲氧苄啶8mg，磺胺甲恶唑40mg）治疗，分2次给药，每组治疗10天。治疗10天后，头孢克洛组70%的患者和TMP-SMX组90%的患者治愈（0.1＞p＞0.05）。与第10天相比，第21天的结果并无改善。我们的数据表明对TMP-SMX有轻微偏好（尽管p不小于0.05），因为它每天只需给药2次，且成本低于头孢克洛。
